Detailed information |
---|
CancerLivER ID | 2123 |
Biomarker | lithocholic acid |
Biomarker Name/Symbol (given in Publication) | lithocholic acid |
Biomolecule | Metabolites |
Subject | Mice |
Degree of Validity | Non-invasive candidate biomarkers in the clinical application of AFLD for health management; but not validated in human patient cohorts |
Experimental Condition | Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled |
Cancer type | Alcoholic fatty liver disease (AFLD) |
Regulation | Upregulated in AFLD |
Level of significance | |
Source | Serum |
PMID | 24171385 |
Type of Biomarker | Potential Predictive * |
Pathway | arachidonic acid pathway, amino acid metabolism |
Cohort | Six-week-old male C57BL/6 (B6) mice (BioLASCO Taiwan Co.) were maintained at the animal housing facility of the Institute of Food Science and Technology, National Taiwan University |
Sensitivity | NA |
Specificity | NA |
Accuracy | NA |
AUC | NA |
Disease | Mice, alcoholic fatty liver disease (AFLD) |
Year of Publication | 2013 |
Clinical trial | NO |
Clinical trial (NCT Number) | NA |